Newspaper editorial: Many pharmaceutical companies develop "me too" drugs, drugs designed to duplicate, more or less, the effect of another company' s product that is already on the market. Some critics object that such development constitutes an unnecessary, redundant use of resources that provides no new benefits to consumers. However, the entry of "me too" drugs into the market can result in a price reduction for the drugs they resemble. Ttherefore, "me too" drugs can indeed benefit consumers. Which one of the following, if true, most strengthens the editorial's argument? ['Pharmaceutical companies often make more money on a "me too" drug than on an original drug.', 'Some pharmaceutical companies lose money on the development of innovative drugs because of the development by other companies of "me too" drugs.', 'Some "me too" drugs turn out to be more effective than the drugs they were designed to imitate.', 'If all pharmaceutical companies developed "me too" drugs, fewer innovative drugs would be developed.']